依达拉奉联合连续性血液滤过治疗重症肺炎临床观察

Clinical observation of severe pneumonia treated with edaravone and continuous veno-venous hemofiltration

目的 观察依达拉奉联合连续性血液滤过（CVVH）治疗重症肺炎的临床疗效.方法 64例重症肺炎患者随机分为两组：对照组32例采用常规治疗;治疗组32例在对照组的基础上加用依达拉奉60 mg/（kg＊d） 持续静脉滴注,2次/d,疗程14 d,同时予行连续性血液滤过治疗.观察患者死亡率、平均住院日、体温、动脉血气分析及白细胞计数（WBC）等变化.结果 依达拉奉联合CVVH治疗组体温恢复正常的时间、白细胞计数恢复正常时间明显短于对照组（P〈0.05）;氧合指数均好于对照组;X线胸片病灶吸收情况、死亡率及平均住院日,治疗组优于对照组.结论 依达拉奉联合CVVH

Objective To observe the clinical curative effect of severe pneumonia with edaravone combined with continuous veno- venous hemofihration（CVVH）. Methods 64 patients with severe pneumonia were divided into two groups at random, control group： 32 cases were treated with routine treatment, and treatment group： 32 cases were treated with routine treatment and edaravone injection（ edaravone 30 mg, bid, for 14 days ）, and CVVH. The clinical situation of patients before and after treatment, mortality rate, hospital days, white blood cell count, body temperature, arterial blood gas analysis were observed. Results In treatment group, the white blood cell counts and body temperature were significantly decreased （ P 〈 0. 05 ）. There was significant difference in mortality rate and hospital days between two groups. PaO2/FiO2 was better in treatment group than in control group. Conclusion The clinical curative effect on severe pneumonia with edaravone combined with CVVH is satisfactory.